NCT Number: NCT00482235
A Study of MK0359 in Patients With Chronic Obstructive Pulmonary Disease (COPD)(0359-016)
A study to test the effect of MK0359 in lessening the symptoms of COPD as compared to salmeterol and placebo.
Looking for future studies?
Notify MeKey information
Conditions
Age range
40 year–75 year
Sex eligibility
All sexes
Study type
Interventional
Phase
Phase 2
Who can participate
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
- You are between the ages of 40 and 75
- You have had a history for at least a year of COPD symptoms
- You have a history of smoking one pack of cigarettes per day for 10 years
Exclusion criteria
- You have been in a research study with an investigational drug or vaccine in the last 4 weeks.
- You have donated blood in the last 4 weeks.
- You have been hospitalized or had major surgery in the last 4 weeks
- You have been treated in the emergency room within the last 2 months or hospitalized within the last 3 months for your COPD symptoms
- You have a history of heart problems in the last 6 months
- You have a history of stomach problems
- You are unwilling to avoid grapefruit juice throughout the study
Treatment and study plan
Sponsors and collaborators
Lead sponsor
Merck Sharp & Dohme LLC
Industry
Registry information
Important dates
- Study start
- 2002
- Primary completion
- 2003
- Study completion
- 2003
- First posted
- Jun 5, 2007
- Registry last updated
- Dec 2, 2015
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Related clinical trials
Published trials that share one or more normalized conditions with this study.
A Phase II Clinical Trial on the Efficacy and Safety of TQC3721 Inhalation Powder
NCT07252908
Chronic Disease, Disease Attributes
Chongqing, Chognqing, China
View Trial DetailsGenerative AI for Medication Counselling and Adherence in Community Pharmacies
NCT07649577
Asthma, Bronchial Diseases
Amman, Jordan
View Trial DetailsA Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Immunogenicity of GSK3862995B Administered as a Single Dose to Healthy Participants of Chinese, Japanese, and European Ancestry
NCT06979518
Chronic Disease, Disease Attributes
Cypress, California, United States
View Trial DetailsDetecting Systemic Carbon Dioxide Levels With a Novel Biosensor
NCT06367686
Apnea, Chronic Disease
Tønsberg, Norway
View Trial Details